

## Apraglutide TFA

Cat. No.:	HY-P1714A
Molecular Formula:	$C_{172}H_{263}N_{43}O_{52} \cdot xC_2HF_3O_2$
Sequence:	His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-{Nle}-{d-Phe}-Thr-Ile-Leu-Asp-Leu-Leu-Ala-Ala-A rg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-NH <sub>2</sub>
Sequence Shortening:	HGDGSFSDE-{Nle}-{d-Phe}-TILDLLAARDFINWLIQTKITD-NH <sub>2</sub> <small>HGDGSFSDE-{Nle}-{d-Phe}-TILDLLAARDFINWLIQTKITD-NH<sub>2</sub> (TFA salt)</small>
Target:	GLP Receptor
Pathway:	GPCR/G Protein
Storage:	Sealed storage, away from moisture Powder    -80°C    2 years -20°C    1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### SOLVENT & SOLUBILITY

In Vitro	H <sub>2</sub> O : 66.67 mg/mL (ultrasonic and adjust pH to 11 with NaOH)
----------	---

### BIOLOGICAL ACTIVITY

Description	Apraglutide TFA (FE 203799 TFA), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum <sup>[1]</sup> .								
In Vivo	<p>Apraglutide (FE 203799; 5 mg/kg/dose, subcutaneously, twice on days 0 and 4 postsurgery) treated piglets are healthy, have significant lower fecal fat and energy losses and exhibit intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth on day 7<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table> <tr> <td>Animal Model:</td><td>NewbornDuroc piglets, 2-5 days old and weighing between 2-2.6 kg<sup>[1]</sup>.</td></tr> <tr> <td>Dosage:</td><td>5 mg/kg/dose.</td></tr> <tr> <td>Administration:</td><td>Subcutaneously, twice on days 0 and 4 postsurgery.</td></tr> <tr> <td>Result:</td><td>On day 7, treated piglets were healthy, had significant lower fecal fat and energy losses and exhibited intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth.</td></tr> </table>	Animal Model:	NewbornDuroc piglets, 2-5 days old and weighing between 2-2.6 kg <sup>[1]</sup> .	Dosage:	5 mg/kg/dose.	Administration:	Subcutaneously, twice on days 0 and 4 postsurgery.	Result:	On day 7, treated piglets were healthy, had significant lower fecal fat and energy losses and exhibited intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth.
Animal Model:	NewbornDuroc piglets, 2-5 days old and weighing between 2-2.6 kg <sup>[1]</sup> .								
Dosage:	5 mg/kg/dose.								
Administration:	Subcutaneously, twice on days 0 and 4 postsurgery.								
Result:	On day 7, treated piglets were healthy, had significant lower fecal fat and energy losses and exhibited intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth.								

### REFERENCES

[1]. Slim GM, et al. Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. JPEN J Parenter Enteral Nutr. 2019 Jan 6.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA